Prominent biotech VCs leap into the political fray

Venture capitalists generally avoid the fray of Washington politics, at least when it comes to the biotech industry. But these are not normal times — in Congress, or in the debate over drug pricing.

As STAT's Nick Florko reports, a group of top biotech venture capitalists are issuing a stark warning to Congress, writing in a letter that they won’t be pouring money into research if Democrats’ signature drug pricing bill becomes law.

Read more.